Divalproex Sodium Tablet, Extended Release
Product Images NDC 70518-1138

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 250mg 70518 1138 00

Label for Divalproex Sodium 250 mg extended-release oral tablets. The label shows a quantity of 30 tablets and includes the NDC number 70518-1138-00. It is repackaged by RemedyRepack Inc. with directions to see the package insert, storage temperature guidance, and a manufacturer listed as Dr. Reddy's in Shreveport, LA. A barcode and a QR code are also visible.*

FDA Label Image

Divalproex Sodium 250mg 70518 1138 01

Divalproex Sodium 250 mg extended-release tablets packaging label by RemedyRepack Inc. The label shows a quantity of 100 tablets, with manufacturer Dr. Reddy's, Shreveport, LA. It includes storage instructions, a barcode, and a QR code for additional product information.*

FDA Label Image

Divalproex Sodium 250mg 70518 1138 02

Label for Divalproex Sodium extended-release tablet, 250 mg strength, quantity of 1. The label includes RX only designation, NDC number 70518-1138-02, manufacturer Dr. Reddy's, and repackager RemedyRepack Inc. It advises keeping the medication out of reach of children, storage temperatures, and to see package insert for directions.*

FDA Label Image

Figure1

A cumulative percentage graph depicting the reduction in CPS rate among patients treated with Divalproex Sodium delayed-release tablets compared to placebo. The x-axis shows the percentage of patients, and the y-axis indicates the percentage reduction in CPS rate, with improvement upward and worsening downward. Two curves represent Divalproex Sodium and placebo responses.*

FDA Label Image

Figure2

A cumulative distribution plot showing the percentage reduction in CPS rate among patients treated with high dose (solid line) and low dose (dashed line) Divalproex Sodium delayed-release tablets. The vertical axis represents percentage reduction from -100% to 100%, with directions indicating improvement or worsening. The horizontal axis shows the percentage of patients from 100% to 0%, with a reference line at no change (0%).*

FDA Label Image

Figure3

A bar graph comparing two groups: Placebo (white bar) and Divalproex Sodium Extended-Release Tablets (black bar). The y-axis shows a numeric scale from 0 to 1.2, with the Divalproex group bar reaching approximately 1.2 and the Placebo group bar reaching 0.6. The graph visually represents a comparative measure between Placebo and Divalproex Sodium Extended-Release Tablets.*

FDA Label Image

Structure

Chemical structure of Divalproex Sodium showing the molecular arrangement with sodium ion and associated alkyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.